Compare Elastic NV (ESTC) vs TG Therapeutics Inc (TGTX) Price & Performance

Elastic N.V. (ESTC) trades at $77.16, up 1.1% with a bullish technical outlook. The stock shows strong profitability with a 76.07% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Institutional activity is mixed, with Amundi increasing its stake while BNY Mellon reduced its position.

The outlook is positive, supported by earnings momentum and strategic partnerships, but risks include high valuation multiples and a recent legal investigation. Analyst consensus is bullish with a $74.21 price target, though the current price exceeds this, indicating potential near-term consolidation. Revenue growth and AI integration present key opportunities for long-term investors.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.